Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review	role of the cannabinoid system in chronic inflammatory pain.	it reduce burden of chronic pain	Anthony AT, Rahmat S, Sangle P, Sandhu O, Khan S. Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review. Cureus. 2020 Sep 14;12(9):e10436. doi: 10.7759/cureus.10436. PMID: 33072446; PMCID: PMC7557112.
Use of cannabidiol (CBD) for the treatment of chronic pain	treatment efficacy of CBD, THC,nabiximols for chronic pain and adverse events with each.		Urits I, Gress K, Charipova K, Habib K, Lee D, Lee C, Jung JW, Kassem H, Cornett E, Paladini A, Varrassi G, Kaye AD, Viswanath O. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):463-477. doi: 10.1016/j.bpa.2020.06.004. Epub 2020 Jul 2. PMID: 33004159.
The Neuroimmunology of Chronic Pain: From Rodents to Humans	neuroimmune signaling mechanisms and novel therapeutic targets in rodent models of chronic pain		Grace PM, Tawfik VL, Svensson CI, Burton MD, Loggia ML, Hutchinson MR. The Neuroimmunology of Chronic Pain: From Rodents to Humans. J Neurosci. 2021 Feb 3;41(5):855-865. doi: 10.1523/JNEUROSCI.1650-20.2020. Epub 2020 Nov 25. PMID: 33239404; PMCID: PMC7880288.
The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial	metered-dose cannabis inhaler delivered precise and low THC doses, produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/ complex-regional pain syndrome (CRPS)		Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, Hayon Y, Eisenberg E. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020 Sep;24(8):1505-1516. doi: 10.1002/ejp.1605. Epub 2020 Jun 12. PMID: 32445190; PMCID: PMC7496774.
Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain	interactions between cannabinoids and pain medication through drug transporters	morphine,codeine,methadone,tramadol..augment analgesia ...in animals	Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. Biomed Res Int. 2020 Aug 13;2020:3902740. doi: 10.1155/2020/3902740. PMID: 32855964; PMCID: PMC7443220.
Cannabis Use in Hospitalized Patients with Chronic Pain	Cannabis use increased substantially from 2011 to 2015	it improves chronic pain in CRP,Trauma,post surgical,spondylosis	Orhurhu V, Urits I, Olusunmade M, Olayinka A, Salisu Orhurhu M, Uwandu C, Aner M, Ogunsola S, Akpala L, Hirji S, Viswanath O, Karri J, Simopoulos T, Gill J. Cannabis Use in Hospitalized Patients with Chronic Pain. Adv Ther. 2020 Aug;37(8):3571-3583. doi: 10.1007/s12325-020-01416-9. Epub 2020 Jul 6. PMID: 32632850; PMCID: PMC7370966.
Cannabis Use and Low-Back Pain: A Systematic Review	analgesic for low-back pain	more research regarding their analgesic effect is needed	First L, Douglas W, Habibi B, Singh JR, Sein MT. Cannabis Use and Low-Back Pain: A Systematic Review. Cannabis Cannabinoid Res. 2020 Dec 15;5(4):283-289. doi: 10.1089/can.2019.0077. PMID: 33381642; PMCID: PMC7759283.
Understanding Cannabis-Based Therapeutics in Sports Medicine	treatment for athletes with chronic pain conditions	difficult for the sport medicine clinicia to recommed cbd dt limited research	Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Understanding Cannabis-Based Therapeutics in Sports Medicine. Sports Health. 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604. Epub 2020 Sep 16. PMID: 32936058; PMCID: PMC7785900.
Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia	cannabis in fibromyalgia:risk benefit	its usage is limited	Berger AA, Keefe J, Winnick A, Gilbert E, Eskander JP, Yazdi C, Kaye AD, Viswanath O, Urits I. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):617-631. doi: 10.1016/j.bpa.2020.08.010. Epub 2020 Aug 15. PMID: 33004171.
Analgesic Effects and Impairment in Locomotor Activity Induced by Cannabinoid/Opioid Combinations in Rat Models of Chronic Pain	antinociceptive effect of combining synthetic cannabinoids with subtherapeutic doses of opioids	t WIN55212 in combination with tramadol produced a significant reduction in the nociceptive response	Alsalem M, Altarifi A, Haddad M, Azab B, Kalbouneh H, Imraish A, Saleh T, El-Salem K. Analgesic Effects and Impairment in Locomotor Activity Induced by Cannabinoid/Opioid Combinations in Rat Models of Chronic Pain. Brain Sci. 2020 Aug 6;10(8):523. doi: 10.3390/brainsci10080523. PMID: 32781705; PMCID: PMC7547378.
Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control	medical cannabis to support opioid tapering	safe introduction and titration of cannabinoids in concert with tapering opioids.	Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, Clarke H, Cooper ZD, Cyr C, Daeninck P, Deshpande A, Ethans K, Flusk D, Le Foll B, Milloy MJ, Moulin DE, Naidoo V, Ong M, Perez J, Rod K, Sealey R, Sulak D, Walsh Z, O'Connell C. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract. 2020 Nov 28:e13871. doi: 10.1111/ijcp.13871. Epub ahead of print. PMID: 33249713.
[Medical cannabinoids and their indications in chronic pain]	Its use is only validated in certain limited cases, in particular spasticity linked to multiple sclerosis and refractory epilepsies. All other prescriptions require a special request to the OFSP	cannabis use is only validated in certain limited cases, in particular spasticity linked to multiple sclerosis and refractory epilepsies. All other prescriptions require a special request to the OFSP. Moreover, cannabinoid intake may produce several dose-dependent side effects	El Faleh-Kayal Y, Suter M, Cachemaille M. Les cannabinoïdes et leurs indications en antalgie chronique [Medical cannabinoids and their indications in chronic pain]. Rev Med Suisse. 2020 Jul 15;16(700):1363-1366. French. PMID: 32672015.
Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?	cannabs in chronic musculoskeletl pain	cannabinoids Therapeutic Advances in Musculoskeletal Disease may be considered as an adjunctive therapy after recommended first- and second-line therapies have failed to provide sufficient efficacy or tolerability	Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M. Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? Ther Adv Musculoskelet Dis. 2020 Jul 2;12:1759720X20937968. doi: 10.1177/1759720X20937968. PMID: 32655704; PMCID: PMC7333482.
Cannabinoids in the Treatment of Back Pain	potential role of cannabinoids in the treatment of back pain.	The significant risk of morbidity, mortality, and dependence secondary to opioid medications have increased the interest in nonopioid medications	Kim TE, Townsend RK, Branch CL, Romero-Sandoval EA, Hsu W. Cannabinoids in the Treatment of Back Pain. Neurosurgery. 2020 Aug 1;87(2):166-175. doi: 10.1093/neuros/nyz573. PMID: 32097466.
Cannabinoid and Opioid Use Among Total Joint Arthroplasty Patients: A 6-Year, Single-Institution Study	total jont arthroplasty pts cannabinoid versus opioid	During a 6-year period, cannabinoid use increased more than 60%, and opioid use decreased approximately 30%.	Denduluri SK, Woolson ST, Indelli PF, Mariano ER, Harris AHS, Giori NJ. Cannabinoid and Opioid Use Among Total Joint Arthroplasty Patients: A 6-Year, Single-Institution Study. Orthopedics. 2021 Jan 1;44(1):e101-e106. doi: 10.3928/01477447-20200928-02. Epub 2020 Oct 1. PMID: 33002174.
Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management	episodic vomiting	It is characterized by stereotypical episodic vomiting in the setting of chronic, daily cannabis use, with cycles decreasing by the cessation of cannabis	Gajendran M, Sifuentes J, Bashashati M, McCallum R. Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management. J Investig Med. 2020 Dec;68(8):1309-1316. doi: 10.1136/jim-2020-001564. Epub 2020 Oct 28. PMID: 33115959.
Use of Cannabis for Self-Management of Chronic Pelvic Pain	cannabidiol in chronic pelvic pain	improvement in symptoms, including pain, cramping, muscle spasms, anxiety, depression, sleep disturbances, libido, and irritability.	Carrubba AR, Ebbert JO, Spaulding AC, DeStephano D, DeStephano CC. Use of Cannabis for Self-Management of Chronic Pelvic Pain. J Womens Health (Larchmt). 2020 Nov 16. doi: 10.1089/jwh.2020.8737. Epub ahead of print. PMID: 33252316.
Cannabis: are there any benefits?	herbal:THC,CBD,Medical:CKMB more benefits	CBMP:pharmacology,evidence,SE	Vickery AW, Finch PM. Cannabis: are there any benefits? Intern Med J. 2020 Nov;50(11):1326-1332. doi: 10.1111/imj.15052. PMID: 33215831.
Cannabinoid use among Americans with MS: Current trends and gaps in knowledge	THC and CBD in MS	Benefit from cannabinoids for sleep and pain were strongly correlated (r ¼ 0.65, p < 0.0001)	Braley TJ, Whibley D, Alschuler KN, Ehde DM, Chervin RD, Clauw DJ, Williams D, Kratz AL. Cannabinoid use among Americans with MS: Current trends and gaps in knowledge. Mult Scler J Exp Transl Clin. 2020 Sep 22;6(3):2055217320959816. doi: 10.1177/2055217320959816. PMID: 33014410; PMCID: PMC7518014.
Current application of cannabidiol (CBD) in the management and treatment of neurological disorders	anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders>>>>Cannabidiol	CBD has shown promise in the treatment of neurological disorders such as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders	Fiani B, Sarhadi KJ, Soula M, Zafar A, Quadri SA. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. Neurol Sci. 2020 Nov;41(11):3085-3098. doi: 10.1007/s10072-020-04514-2. Epub 2020 Jun 16. PMID: 32556748.
Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression	cannabiinoids in neuropathic versus non neuropathic pain	mean pain score (scale 0-10) reduction of -0.70 (p < 0.001, random effect). Meta-regression showed that analgesic efficacy was similar for neuropathic and non-neuropathic pain (Difference = -0.14, p = 0.262	Wong SSC, Chan WS, Cheung CW. Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression. J Neuroimmune Pharmacol. 2020 Dec;15(4):801-829. doi: 10.1007/s11481-020-09905-y. Epub 2020 Mar 14. PMID: 32172501.
CBD for the treatment of pain: What is the evidence?	why CBD IS better	there is insufficient evidence to recommend CBD for the treatment of pain	Svensson CK. CBD for the treatment of pain: What is the evidence? J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):e80-e83. doi: 10.1016/j.japh.2020.06.009. Epub 2020 Jul 4. PMID: 32636158.
Cannabinoids in multiple sclerosis: A neurophysiological analysis	oral spray containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in MS	The THC-CBD spray improved spasticity and pain in secondary progressive MS patients.	Vecchio D, Varrasi C, Virgilio E, Spagarino A, Naldi P, Cantello R. Cannabinoids in multiple sclerosis: A neurophysiological analysis. Acta Neurol Scand. 2020 Oct;142(4):333-338. doi: 10.1111/ane.13313. Epub 2020 Jul 21. PMID: 32632918.
Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review	mechanisms of action of the phytocannabinoids, especially THC and CBD. the indications and adverse effects	THC acts as a partial agonist at cannabinoid 1/2 receptors (CB1/2). It is responsible for the characteristic effects of cannabis, such as euphoria, relaxation, and changes in perceptions. THC can also produce dysphoria, anxiety, and psychotic symptoms. . CBD acts as a noncompetitive negative allosteric modulator of the CB1 receptor, as an inverse agonist of the CB2 receptor, and as an inhibitor of the reuptake of the endocannabinoid anandamide.. CBD does not produce the typical effects associated with THC.	Dos Santos RG, Hallak JEC, Crippa JAS. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. Adv Exp Med Biol. 2021;1264:29-45. doi: 10.1007/978-3-030-57369-0_3. PMID: 33332002.
Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians	cannabinoids' diverse mechanisms of action as it pertains to nociception modulation	Cannabinoids-opioids cross-modulation and synergy contribute significantly to tolerance and antinociceptive effects of cannabinoids. ' cb diverse mechanisms of action as it pertains to nociception modulation	Narouze S. Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians. Reg Anesth Pain Med. 2021 Mar;46(3):240-250. doi: 10.1136/rapm-2020-102114. Epub 2020 Nov 25. PMID: 33239391.
Medical cannabis and cognitive performance in middle to old adults treated for chronic pain	long-term medical cannabis (MC) use and cognitive function	whole plant MC does not have a widespread impact on cognition in older chronic pain patients	Sznitman SR, Vulfsons S, Meiri D, Weinstein G. Medical cannabis and cognitive performance in middle to old adults treated for chronic pain. Drug Alcohol Rev. 2021 Feb;40(2):272-280. doi: 10.1111/dar.13171. Epub 2020 Sep 22. PMID: 32964502.
Sex differences and the endocannabinoid system in pain		Female rodents have generally been found to be more sensitive to the effects of Δ9-THC	Blanton HL, Barnes RC, McHann MC, Bilbrey JA, Wilkerson JL, Guindon J. Sex differences and the endocannabinoid system in pain. Pharmacol Biochem Behav. 2021 Mar;202:173107. doi: 10.1016/j.pbb.2021.173107. Epub 2021 Jan 12. PMID: 33444598; PMCID: PMC8216879.
Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population	THC and CBD in palliative	Approximately a quarter of outpatient palliative care patients use THC or CBD, often on a daily basis.	Highet BH, Lesser ER, Johnson PW, Kaur JS. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population. Am J Hosp Palliat Care. 2020 Aug;37(8):589-593. doi: 10.1177/1049909119900378. Epub 2020 Jan 27. PMID: 31986898.
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial	thc rich oil in fibromyalgia	the cannabis group presented a statistically significant reduction, going from 75.5 to 30.5 points (P< 0.001). At the same time, the placebo group maintained its score (P¼ 0.07). Furthermore, in an isolated analysis of FIQ items, the cannabis group presented a reduction in mean values on the “feel good,” “pain,” and “fatigue” items. The placebo group presented a reduction in mean values on the “depression” item	Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pain Med. 2020 Oct 1;21(10):2212-2218. doi: 10.1093/pm/pnaa303. PMID: 33118602; PMCID: PMC7593796.
The cannabinoid CB 2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence	synergy with morphine	cannabinoid CB2 receptor activation enhances the therapeutic properties of opioids while attenuating unwanted side-effects such as reward and dependence that occur with sustained opioid treatment.	Iyer V, Slivicki RA, Thomaz AC, Crystal JD, Mackie K, Hohmann AG. The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. Eur J Pharmacol. 2020 Nov 5;886:173544. doi: 10.1016/j.ejphar.2020.173544. Epub 2020 Sep 5. PMID: 32896549; PMCID: PMC7694697.
Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside			Meng H, Deshpande A. Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside. BJA Educ. 2020 Sep;20(9):305-311. doi: 10.1016/j.bjae.2020.05.002. Epub 2020 Jul 21. PMID: 33456965; PMCID: PMC7807923.
Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease	cannabinoid in alzheimer disease	Cannabinoids act by targeting several signaling processes, such as pain, abnormal processing of Ab and tau, neuroinflammation, excitotoxicity, oxidative stress, and mitochondrial dysfunction, which play a pivotal role in the management of AD. Cannabinoids also ameliorate behavioral and cognitive dysfunctions. T	Uddin MS, Mamun AA, Sumsuzzman DM, Ashraf GM, Perveen A, Bungau SG, Mousa SA, El-Seedi HR, Bin-Jumah MN, Abdel-Daim MM. Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease. Front Pharmacol. 2020 Jul 22;11:1097. doi: 10.3389/fphar.2020.01097. PMID: 32792944; PMCID: PMC7387504.
Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials		This review concludes that cannabinoids may have a potential role in chronic pain management	Longo R, Oudshoorn A, Befus D. Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials. Pain Manag Nurs. 2021 Apr;22(2):141-149. doi: 10.1016/j.pmn.2020.11.006. Epub 2021 Jan 19. PMID: 33353819.
General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews		harms associated with cannabis and cannabinoids generally relevant to individuals being treated for pain. including psychiatric and psychosocial harms, cognitive/behavioral effects, motor vehicle accidents, cardiovascular, respiratory, cancer-related, maternal/fetal, and general harms	Mohiuddin M, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Haroutounian S, Moore A, Rice ASC, Wallace M, Park R, Gilron I. General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. Pain. 2021 Jul 1;162(Suppl 1):S80-S96. doi: 10.1097/j.pain.0000000000002000. PMID: 32941319.
The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage	cannabis and opioids	cannabis use worked as an alternative to prescription opioids in just over half of patients with low back pain and as an adjunct to diminish use in some chronic opioid users.	Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM. The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage. Cannabis Cannabinoid Res. 2020 Sep 2;5(3):263-270. doi: 10.1089/can.2019.0039. PMID: 32923663; PMCID: PMC7480723.